Corcept Therapeutics
CORT
63.62
-1.36
-2.09%
Corcept Therapeutics
US · CORT
#1285 by market cap
Listed 1970
63.62
-1.36
-2.09%
Periodic snapshot; not a real-time feed.
· 2026-11-20 19:30
✦ Quant Ownership Signal how this is computed
Mixed / stable
- The number of reporting institutions decreased by 2 in the most recent period (2026/Q4).
- Total institutional ownership (as a % of shares) was little changed.
Ownership vs. money flow
AlignedInstitutions trimmed shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two line up.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Institutional ownership
- Held by institutions
- 74.20% -0.06pp
- Institutions
- 584 -2
- As of
- 2026/Q4 vs. prior period
Holder types
Mutual Fund56.75%
Hedge Fund12.04%
Individual/Insider10.54%
Private Company1.66%
Public Company1.33%
Government Pension Fund1.06%
Sovereign Wealth Fund0.45%
VC/PE Fund0.41%
Insurance Company0.29%
Other15.46%
Top holders as of 2026-09-30
BlackRock
9.32% · 10.20M sh
Ingalls & Snyder, LLC
7.01% · 7.67M sh
George Baker
5.07% · 5.55M sh
Vanguard Capital Management, LLC
4.54% · 4.97M sh
Renaissance Technologies Corp.
4.43% · 4.85M sh
Vanguard Portfolio Management, LLC
4.36% · 4.78M sh
Parallel Advisors, LLC
3.57% · 3.90M sh
AQR Capital Management
3.29% · 3.60M sh
FMR
3.19% · 3.49M sh
Joseph Belanoff
2.62% · 2.87M sh
State Street Global Advisors
2.84% · 3.10M sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 10 buys · 35 sells
| Name | Role | Stake |
|---|---|---|
| George Baker | Independent Director | 5.07% |
| Joseph Belanoff | Chief Executive Officer | 2.62% |
| James Wilson | Independent Chairperson | 1.32% |
| David Mahoney | Independent Director | 1.06% |
| Hazel Hunt | Chief Scientific Officer | 0.23% |
| Sean Maduck | Former President of Endocrinology | 0.12% |
| Gary Robb | Chief Business Officer & Secretary | 0.09% |
| Atabak Mokari | Chief Financial Officer | 0.01% |
| Joseph Lyon | Chief Technology & Accounting Officer | 0.01% |
| Justin Gunn | President of Endocrinology | 0.00% |
| William Guyer | Chief Development Officer | 0.00% |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-11-09 | Daniel Swisher | Independent Director | Derivative Exercise and Sale | -1,500 | $10.50–74.07 |
| 2026-11-02 | Sean Maduck | Former President of Endocrinology | Derivative Exercise and Sale | -25,000 | $8.27–82.68 |
| 2026-11-01 | Roberto Vieira | President of Oncology | Derivative Exercise and Sale | -8,333 | $21.63–81.52 |
| 2026-10-14 | James Wilson | Independent Chairperson | Automatic Disposition | -10,000 | $114.48–116.30 |
| 2026-10-01 | Sean Maduck | Former President of Endocrinology | Derivative Exercise and Sale | -25,000 | $8.27–116.55 |
| 2026-10-01 | Joseph Lyon | Chief Technology & Accounting Officer | Derivative Exercise and Sale | -10,000 | $13.56–116.54 |
| 2026-10-01 | Roberto Vieira | President of Oncology | Derivative Exercise and Sale | -8,333 | $21.63–116.59 |
| 2026-09-30 | Joseph Lyon | Chief Technology & Accounting Officer | Intent to Sell (Form 144) | -10,000 | $115.23 |
| 2026-09-30 | Justin Gunn | President of Endocrinology | Other Derivative Acquisition | +100,000 | $114.03 |
| 2026-09-30 | Justin Gunn | President of Endocrinology | Initial Statement of Beneficial | 0 | -- |
| 2026-09-23 | Gary Robb | Chief Business Officer & Secretary | Other Acquisition | +10,000 | -- |
| 2026-09-23 | Gary Robb | Chief Business Officer & Secretary | Other Disposition | -17,100 | -- |
| 2026-09-16 | Gary Robb | Chief Business Officer & Secretary | Derivative Exercise and Retained | +17,493 | $8.27 |
| 2026-09-15 | Roberto Vieira | President of Oncology | Automatic Disposition | -296 | $100.82 |
| 2026-09-14 | James Wilson | Independent Chairperson | Automatic Disposition | -10,000 | $110.27–111.70 |
| 2026-09-13 | Joseph Lyon | Chief Technology & Accounting Officer | Derivative Exercise and Sale | -10,000 | $11.35–114.12 |
| 2026-09-01 | Atabak Mokari | Chief Financial Officer | Sale to Issuer | -102 | $113.38 |
| 2026-09-01 | Gary Robb | Chief Business Officer & Secretary | Sale to Issuer | -91 | $113.38 |
| 2026-09-01 | Sean Maduck | Former President of Endocrinology | Sale to Issuer | -117 | $113.38 |
| 2026-09-01 | Joseph Lyon | Chief Technology & Accounting Officer | Sale to Issuer | -72 | $113.38 |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.
Corcept Therapeutics discussion 0 comments